Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. All rights reserved. BELLUS Health to Present at the Eleventh International Virtual Cough Symposium. The AP news staff was not involved in its creation. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. Get the hottest stocks to trade every day before the … The company’s stock price has collected -10.59% of loss in the last five trading sessions. Last month, Jefferies hosted an investor call with a cough specialist who, according to the investment bank, expected the Phase 2 study to read out positive and show efficacy data "as good as" Merck's gefapixant, which works in a similar way to Bellus' drug. BELLUS Health is developing BLU-5937, a P2X3 antagonist, to help people with chronic cough and other afferent hypersensitization-related disorders. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or … Press Release Feb 22, 2021 12:00 UTC. Detailed price information for Bellus Health Inc (BLU-T) from The Globe and Mail including charting and trades. Press release content from Business Wire. December 14, 2020 Business Wire Press Release BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with … March 23, 2020 GMT. 02/25/2021 16:01. Press Release For immediate distribution BELLUS HEALTH AND CELTIC THERAPEUTICS ENTER AGREEMENT FOR BELLUS’ DRUG CANDIDATE KIACTA™ KIACTA™ advancing to a confirmatory Phase III clinical trial LAVAL, Quebec, Canada. Press Release Dec 23, 2020 21:51 UTC. BELLUS Health Establishes At-the-Market Facility LAVAL, Quebec--(Business Wire)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health… BELLUS Health (BLU): FY GAAP EPS of -$0.54 misses by $0.01.Revenue of $15kCash, cash equivalents and short-term investments of $98.3M.Press Release Press Release reported on 12/14/20 that BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus … Original press release here – BELLUS to own 100% of BLU-5937 and related P2X3 antagonists intellectual property with no future payments due – – 4.77 million BELLUS Health common shares to be issued in consideration – LAVAL, Quebec–(BUSINESS WIRE)–Mar. Press Releases. 3.9400 0.00 (0.00%)Pre-Market: 7:00AM EST, Subscribe to Premium to view Fair Value for BLU. Dive Insight: Monday's announcement might have taken Bellus investors by surprise. The MarketWatch News Department was not involved in the creation of this content. Chronic cough, the lead indication for BLU-5937, is a cough lasting more than eight weeks and is associated with significant adverse physical, social and psychosocial effects on health and quality of life. LAVAL, Quebec — BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2019. Press Release reported on 02/25/21 that BELLUS Health Reports Year 2020 Financial Results and Business Highlights. BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today … BELLUS Health announced the appointment of Dr. Catherine Bonuccelli, MD to the role of Chief Medical Officer. BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the tre BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences LAVAL, Quebec--(Business Wire)--BELLUS Health Inc. … 18, 2021 /CNW/ - Trading resumes in: Company: BELLUS Health Inc.TSX Symbol: BLU All Issues: NoResumption (ET): 12:54 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. April 29, 2010 – BELLUS Health … BELLUS Health Announces First Patient Enrolled in Phase 2 Study of BLU-5937 for the Treatment of Refractory Chronic Cough & Pursuit of Second Indication in Chronic Pruritus, BELLUS Health Convenes KOL Meeting to Discuss the State of Chronic Cough Treatment, BELLUS Health Presents Phase 1 Data for BLU-5937, its Lead Product Candidate for the Treatment of Refractory Chronic Cough, at the American Thoracic Society International Conference, BELLUS Health to Present at Three Upcoming Healthcare Investor Conferences, BELLUS Health Provides Update on Its Chronic Cough Drug Candidate BLU-5937 and Reports Financial and Operating Results for the First Quarter Ended March 31, 2019, BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences, BELLUS Health Announces Clearance of U.S. IND for BLU-5937 Phase 2 Study in Chronic Cough Patients, BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan. : (450) 680-4500Fax: (450) 680-4501info@bellushealth.com. Dr. Bonuccelli is a pediatric pulmonologist that brings over 20 years of pharmaceutical experience with significant expertise in clinical and product development of respiratory and non-respiratory products. © 2021 Verizon Media. Currency in USD, Trade prices are not sourced from all markets. Press Releases Year. BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutic Press release content from Business Wire. © 2021 BELLUS Health Inc. All Rights Reserved. BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences. Business Wire. BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. Press Release BELLUS Health Announces First Patient Dosed in its Phase 2 BLUEPRINT Trial of BLU-5937 for the Treatment of Chronic Pruritus Associated with Atopic Dermatitis 12/08/20 Research Reports. BELLUS Health Inc.275 Armand-Frappier Blvd.Laval, QuebecCanada H7V 4A7, Tel. January 14, 2021 GMT. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the "Company" or "BELLUS Health"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in … The Company's product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. * Press release - Bellus Health announces the sale of subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals * Bellus Health Inc - deal for total consideration of CA$2.7 million BELLUS Health Announces Transaction to Acquire Remaining Intellectual Property Rights to BLU-5937 from adMare BioInnovations. The company’s stock price has collected 5.03% of gains in the last five trading sessions. About BELLUS Health (www.bellushealth.com) BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The MarketWatch News Department was not involved in the creation of this content. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the year ending December 31, 2020. BELLUS Health believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. 2/25/21 ... 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related … The AP news staff was not involved in its creation. BELLUS Health Presents 2018 Highlights and 2019 Corporate Plan BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today presented its 2018 achievements and corporate priorities for 2019. CONTACT: Danny Matthews. BELLUS Health Inc. (NASDAQ:BLU) went down by -4.97% from its latest closing price compared to the recent 1-year high of $12.03. LAVAL, Quebec--(BUSINESS WIRE)--Mar 23, … BELLUS Health Inc. (NASDAQ:BLU) went up by 7.46% from its latest closing price compared to the recent 1-year high of $12.03. BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences.
Shenzhen Gdp 2019 Usd, Gift Boxes And Bags, Putty Meaning In Nepali, Celtics Vs Cavs 2017 Playoffs, Oral Anticoagulants Classification, Never Scared - Chris Rock, Stonewall Meaning In Arabic, Looney Tunes 90th Anniversary,